[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"drug-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:drug-therapy":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,39,73,104,134,166,192,218],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100644182","analysis-of-efficacy-and-outcomes-of-immunotherapy-for-malignant-tumors-a-prospective-non-interventional-clinical-study-100644182",false,"NCT07665697","Analysis of Efficacy and Outcomes of Immunotherapy for Malignant Tumors: A Prospective Non-interventional Clinical Study","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Histologically or cytologically confirmed malignant tumor;\n3. Planned to receive immune checkpoint inhibitor (e.g., PD-1\u002FPD-L1 inhibitor)-based therapy (monotherapy or in combination with chemotherapy\u002Ftargeted therapy\u002Fradiotherapy, etc.);\n4. At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1);\n5. Adequate organ function (with reference to laboratory tests such as complete blood count, liver and kidney function tests);\n6. Voluntary participation in this study, signed informed consent, and willingness to comply with follow-up.\n\nExclusion Criteria:\n\n1. Active autoimmune disease requiring systemic immunosuppressive therapy (physiological doses of glucocorticoid replacement therapy or inhaled steroids are permitted);\n2. Active, uncontrolled severe infection, or known human immunodeficiency virus (HIV) infection;\n3. Pregnant or breastfeeding women;\n4. Any unstable systemic disease (including but not limited to severe cardiac, hepatic, or renal insufficiency).","ALL","18 Years",{"count":18,"type":19},500,"ESTIMATED","OBSERVATIONAL","The population receiving immunotherapy is heterogeneous. Multiple factors, including combination treatment modalities, influence the immune response, and survival outcomes also vary among individuals receiving immunotherapy. The aim of this study is to develop and validate a clinical prediction model that can predict survival outcomes of immunotherapy for malignant tumors, and to assess the calibration and discrimination of this model in a prospective independent cohort.",[23,24,25],"Neoplasms","Drug Therapy","Immune Checkpoint Inhibitors (ICIs)","NOT_YET_RECRUITING","2026-06-19",{"date":29,"type":30},"2026-06-24","ACTUAL",{"date":32,"type":19},"2026-06-30",{"date":34,"type":19},"2029-06-15",{"name":36,"class":37},"Sichuan University","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":45,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":57,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":38},"100533265","phase-2-phase-ii-trial-of-neoadjuvant-chemotherapy-nac-alone-or-in-combination-with-immunotherapy-vaccine-prgn-2009-in-subjects-with-newly-diagnosed-hpv-associated-oropharyngeal-head-and-neck-cancer-100533265","NCT06223568","Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer","* INCLUSION CRITERIA:\n* Histologically or cytologically confirmed surgically resectable newly diagnosed stage I (cT1-2, N0-1) or II (T1-3, N0-2), M0 oropharyngeal squamous cell carcinoma. Note: Pathological report of cancer diagnosis may be from the primary tumor or from a metastatic cervical lymph node.\n* History of HPV-positive status determined by a standard-of-care HPV testing. Note: All participants with high-risk HPV serotypes are eligible.\n* Age \\>= 18 years.\n* ECOG performance status \\\u003C= 2.\n* Individuals who smoke currently must smoke \\\u003C10 pack years. Note: Former smokers with any pack-year history are eligible if quit smoking \\>10 years before study treatment initiation. Former smokers who quit \\\u003C10 years before study treatment initiation must have smoked \\\u003C10 pack years.\n* Planned for cancer removal surgery per standard of care (SOC) and individual had agreed for the cancer removal surgery.\n\n  * Individuals must have adequate organ and marrow function as defined below:\n  * Absolute neutrophil count (ANC) \\>= 1.5 x 10\\^9\u002FL\n  * Hemoglobin (Hgb) \\>= 9.0 g\u002FdL\n  * Platelet count \\>= 100 x 10\\^9\u002FL\n  * Creatinine \\\u003C= 1.2 x upper limit of normal (ULN) OR calculated creatinine clearance \\>=55 mL\u002Fmin\u002F1.73m\\^2 by Cockcroft-Gault formula\n* Total bilirubin \\\u003C= 1 x ULN, or \\\u003C= 3 x ULN in patients with known or suspected Gilbert's Syndrome\n* Alanine aminotransferase (ALT) \\\u003C= 1.5 x ULN\n* Aspartate aminotransferase (AST) \\\u003C= 1.5 x ULN\n* Individuals serologically positive for human immunodeficiency virus (HIV) must:\n\n  * be on effective anti-retroviral therapy for at least 4 weeks; and\n  * have undetectable viral load; and\n  * have the CD4 count \\>=200 cells\u002FmicroL; and\n  * have no reported opportunistic infections or Castleman s disease within 12 months prior to study treatment initiation\n* Individuals serologically positive for Hepatitis C virus (HCV) or Hepatitis B virus (HCB) must have an undetectable viral load.\n* Individuals of child-bearing potential (IOCBP) must agree to use a highly effective method of contraception (hormonal, intrauterine device (IUD), surgical sterilization, abstinence) for the duration of the study treatment and up to 2 months after the last dose of PRGN-2009 and an effective method of contraception (barrier, hormonal, intrauterine device (IUD), surgical sterilization, abstinence) for 14 months after the last dose of cisplatin\u002Fdocetaxel. Note: IOCBP is defined as any woman who has experienced menarche and has not had a hysterectomy or bilateral oophorectomy or is not postmenopausal (amenorrheic 12 months or more following cessation of exogenous hormonal treatments; if \\\u003C50 years old and need follicle stimulating hormone \\[FSH\\] in the post-menopausal range).\n\nMen must agree to use a highly effective method of contraception (surgical sterilization, abstinence) for the duration of the study treatment and up to 2 months after the last dose of PRGN-2009 and an effective method of contraception (barrier, surgical sterilization, abstinence) for the duration of the study treatment and up to 11 months after the last dose of the study drug(s). We also will recommend men on treatment with PRGN-2009 with female partners of childbearing potential ask female partners to be on highly effective birth control (hormonal, intrauterine device (IUD), surgical sterilization) during PRGN-2009 treatment and 2 months after that.\n\n* Breastfeeding individuals must be willing to discontinue breastfeeding from study treatment initiation through 2 months after the last dose of the study drug(s).\n* Individuals must have a tumor site that is amenable to biopsy and be willing to undergo pre- treatment biopsy for research purposes.\n* Individuals must be willing to undergo pre-treatment PET\u002FCT imaging study.\n* The ability of an individual to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Peripheral motor or sensory neuropathy \\> Grade 2 per Common Terminology Criteria for Adverse Events (CTCAE) v.5 at screening.\n* Prior therapy with an investigational drug, live vaccine, chemotherapy, immunotherapy, or any prior radiotherapy (except for palliative bone-directed therapy) within 4 weeks prior to the first study drug administration. Note: Participants may continue adjuvant hormonal therapy in the setting of a definitively treated cancer (e.g., breast).\n* Prior therapy with any medications or substances that are moderate or strong inducers or moderate or strong inhibitors of cytochrome P450 (CYP3A) https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FDevelopmentApprovalProcess\u002FDevelopmentResources\u002FDrugInteractionsLabeling\u002Fucm093664.htm#table2-2,table3-3,table5-2 within 2 weeks prior to the first study drug administration.\n* History of allergic reactions attributed to compounds of similar chemical or biological composition to drugs used in the study.\n* Systemic (intravenous or oral) glucocorticoid (except for physiologic doses of corticosteroids, i.e., \\\u003C= the equivalent of prednisone 10 mg\u002Fday) or other immunosuppressors such as azathioprine or cyclosporin A within 1 week prior to study treatment initiation. Note: Glucocorticoids as premedication for contrast-enhanced studies are allowed.\n* Second malignancy active within the previous 2 years except for indolent or locally curable malignancy that is currently considered cured and\u002For does not require an additional standard of care treatment, such as, but not limited to, cutaneous basal or squamous cell carcinoma, superficial bladder cancer, or cervical carcinoma in situ, or an incidental histological finding of prostate cancer or differentiated thyroid cancer.\n* Prior allogenic tissue\u002Fsolid organ transplant.\n* History of heart failure.\n* Positive beta-human chorionic gonadotropin (beta-HCG) serum or urine pregnancy test performed in females of childbearing potential at screening.\n* Uncontrolled intercurrent illness or medical condition(s) evaluated by medical history and physical exam or situations that are not stable (e.g., recent hospitalization, Emergency Room visit or undergoing medication changes) that would potentially increase risk for the participant.","120 Years",{"count":47,"type":19},70,"INTERVENTIONAL",[50],"PHASE2","Background:\n\nThroat cancer is a common tumor that can occur in people infected with the human papilloma virus (HPV). Most people with this cancer survive more than 5 years with standard chemotherapy drugs plus radiation. But radiation can cause serious adverse effects. Researchers believe that adding a vaccine (PRGN-2009) to this drug therapy may improve survival without the need for radiation.\n\nObjective:\n\nTo test a study vaccine combined with standard chemotherapy in patients with HPV-associated throat cancers.\n\nEligibility:\n\nPeople aged 18 years and older with newly diagnosed throat cancer associated with HPV.\n\nDesign:\n\nParticipants will be screened. They will have a physical exam and blood tests. They will have imaging scans and tests of their heart function and hearing. They will provide a sample of tissue from their tumor. A recent sample may be used; if none is available, a new sample will be taken.\n\nAll participants will get two common drugs for treating cancer. These drugs are given through a tube attached to a needle inserted into a vein in the arm. Participants will receive these drugs on the first day of three 3-week cycles.\n\nHalf of the participants will also get the vaccine. PRGN-2009 is injected under the skin in the arm. They will get these shots 4 times: 7 days before the start of the first cycle and on the 11th day of each cycle.\n\nParticipants will have standard surgery to remove their tumors 3 to 6 weeks after completing the study treatment. They will have follow-up visits 3, 6, 12, and 24 months after their surgery.\n\n...",[53,54,55,24,56],"Squamous Cell Carcinoma of the Head and Neck","Oropharynx","Human Papillomavirus Viruses","Cancer Vaccine",[58,59,60,61],"Neoadjuvant Chemotherapy","Oropharynx Cancer","Human Papillomavirus","Therapeutic Vaccine","RECRUITING","2026-06-09",{"date":65,"type":30},"2026-06-10",{"date":67,"type":30},"2024-06-10",{"date":69,"type":19},"2028-01-10",{"name":71,"class":72},"National Cancer Institute (NCI)","NIH",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":48,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":38},"100399257","phase-4-extended-alternate-day-antipsychotic-dosing-100399257","NCT04478838","\"Extended\" (Alternate Day) Antipsychotic Dosing","\"Re-examining Maintenance Antipsychotic Treatment in Schizophrenia: \"Extended\" Antipsychotic Dosing\"","Inclusion Criteria:\n\n(i) A primary diagnosis of a Schizophrenia Spectrum or Other Psychotic Disorder as defined by the DSM-5 diagnosis and confirmed by the MINI (Version 7.0.2)\n\n(ii) age 18 or older\n\n(iii) female participants of childbearing potential must be using a reliable method of contraception and have a negative pregnancy test at the time of enrolment and must, in the investigator's opinion, practice a clinically accepted, reliable method of contraception during this study. Male participants must not father a baby during their time in the study\n\n(iv) ability to communicate in English\n\n(v) capacity to provide written, informed consent, as assessed using the MacCAT-CR at time of consent\n\n(vi) stabilized as outpatients with a single oral AP (risperidone or olanzapine or paliperidone\\*) at the same dose for ≥3 months i. On a prescribed risperidone dose of between 1-6mg, or a prescribed olanzapine dose of between 5-20mg, or a prescribed paliperidone 3-12mg\n\n(vii) evidence of adherence with current AP treatment\n\nExclusion Criteria:\n\n(i) exposure to a depot AP within 1 year (i.e., no depot AP injection within the last year)\n\n(ii) Current diagnosis of substance use disorder according to DSM-5 criteria (verified through the MINI for Psychotic Disorders (Version 7.0.2) and a positive drug screen for street and \u002For prescription drugs not prescribed to the participant by treating physicians\n\n(iii) ECT within the last 3 months\n\n(iv) pregnancy or lactation\n\n(v) neurological condition (dementia including Alzheimer's disease, multiple sclerosis, epilepsy, stroke, or traumatic brain injury)\n\n(vi) allergy to the study drugs and their excipients\n\n(vii) allergy (e.g., galactosaemia) or severe intolerance to lactose\n\n(viii) negative urine drug screen result for Olanzapine or Risperidone or Paliperidone (if applicable)",{"count":81,"type":19},120,[83],"PHASE4","The study wishes to examine whether \"extended\" antipsychotic treatment, in this case, antipsychotic treatment every other day, is as effective as daily treatment. It is also evaluating whether there may be differences in terms of side effects.\n\nParticipants will be randomly assigned to either the treatment as usual group (i.e., taking antipsychotic daily) or the extended dosing group (i.e., taking antipsychotic one day on, one day off). That means, like flipping a coin, there is a 50\u002F50 chance that participants will continue on daily dosing of your antipsychotic or have it switched to every other day dosing.\n\nThis study will last for 1 year. Participants will be evaluated at the beginning and every two weeks during the first 6 months, with visits once every 4 weeks for the final 6 months. In total, participants will make 22 visits over 52 weeks to the investigator's office.\n\nThe investigators hypothesize that with ED, there will be no change in symptom severity but improvement in the frequency and severity of side effects, wellbeing, and functioning.",[86,87,24,88],"Schizophrenia and Related Disorders","Drug Administration Schedule","Antipsychotic Agents",[90,91,92,93,94],"Extended Dosing","Alternate day dosing","Olanzapine","Risperidone","Paliperidone","2026-04-08",{"date":97,"type":30},"2026-04-13",{"date":99,"type":30},"2022-06-06",{"date":101,"type":19},"2028-09-30",{"name":103,"class":37},"Centre for Addiction and Mental Health",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":15,"minAge":112,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":48,"phases":115,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":38},"100591642","phase-2-efficacy-of-trazodone-to-treat-insomnia-in-older-adults-tradition-study-100591642","NCT06983080","Efficacy of Trazodone to Treat Insomnia in Older Adults (TRADITION Study)","The Efficacy of Trazodone for the Treatment of Insomnia in Older Adults: A Randomized Controlled Trial (The TRADITION Study)","TRADITION","Inclusion Criteria:\n\n* Individuals aged 65 or older in an outpatient setting\n* Insomnia according to the criteria of the ICSD-3R\n\nExclusion Criteria:\n\n* Contraindication to trazodone (hypersensitivity)\n* Presence of a ventricular cardiac arrhythmia (e.g., torsades de pointes)\n* Recent myocardial infarction (\\\u003C 6 months)\n* Substances that may alter sleep (hypnotics or any other medication intended to induce sleep, such as mirtazapine or quetiapine, corticosteroids, melatonin, psychostimulant drugs)\n* Active, unstable psychiatric disorder\n* Initiation or titration of an antidepressant within the past 6 months\n* Cognitive-behavioral therapy ongoing or planned during the study period\n* Major neurocognitive disorder (NCD) moderate or severe, or other cognitive disorders that may prevent the participant from being able to participate in the study, according to the judgment of the evaluating physician\n* Parkinson's disease\n* Priapism\n* Known angle-closure glaucoma\n* Symptomatic restless leg syndrome \\> 3 times per week\n* QTc interval \\> 500 ms\n* Parasomnias, dyssomnias other than insomnia\n* Severe sleep apnea with AHI \\> 30 without CPAP treatment\n* Use of a monoamine oxidase inhibitor\n* Use of a strong CYP 3A4 inducer or inhibitor\n* Hospitalized individuals\n* Seizure within the past 6 months\n* History of orthostatic hypotension\n* History of delirium within the last 6 months\n* Consumption of \\> 14 alcoholic drinks per day or use of alcohol to induce sleep.","65 Years",{"count":114,"type":19},40,[50],"This study aims to evaluate how effective trazodone is in treating insomnia in adults aged 65 years and older. The main question it aims to answer is :\n\n\\- Is trazodone more effective than a placebo in reducing the severity of insomnia symptoms in older adults?\n\nParticipants will :\n\n* Take 25 to 50 mg of trazodone or a matching placebo before bed for 28 days. After a 2-week break, they will then take the other medication for another 28 days.\n* Visit the clinic three times for checkup and test\n* Complete a sleep diary and wear an actimeter during the night.",[118,119,24],"Insomnia Chronic","Older People",[121,122,123,124],"insomia","Trazodone","Older adults","randomized controlled trial","2025-12-02",{"date":127,"type":30},"2025-12-08",{"date":129,"type":30},"2025-11-10",{"date":131,"type":19},"2027-12",{"name":133,"class":37},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":48,"phases":144,"briefSummary":145,"conditions":146,"keywords":150,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":161,"leadSponsor":163,"locationsCount":165},"100557549","phase-2-efficacy-and-resistant-mechanism-of-eribulin-and-bevacizumab-for-advanced-her2-negative-breast-cancer-100557549","NCT06539559","Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer","Efficacy, Adverse Events and Resistant Mechanism of Eribulin Combined With or Without Bevacizumab for Advanced HER2 Negative Breast Cancer Patients, an Open-label, Randomized, Multi-center PhaseⅡ Clinical Trial.","Inclusion Criteria:\n\n1. Age ≥18 years old，and ≤75 years old.\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n3. Expected survival period not less than 12 weeks.\n4. At least 1 measurable lesion according to RECIST 1.1 standard.\n5. previously treated with taxanes and\u002For anthracycline drugs in any stage of breast cancer.\n6. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) validated HER2 negative, including IHC- and IHC 1+\u002F2+ with FISH negative.\n7. at least prior 1 line of chemotherapy in the advanced stage.\n8. The organ function must meet the following requirements：\n\n(1). Blood Routine\n\n* ANC≥1.5×109\u002FL；\n* PLT≥90×109\u002FL；\n* Hb≥90 g\u002FL；\n\n  (2). Blood Biochemistry\n* TBIL≤1.5×ULN；\n* ALT and AST≤2×ULN；ALT和AST≤5×ULN for patients with liver metastasis；\n* BUN and Cr≤1.5×ULN and the Creatinine Clearance Rate ≥50 mL\u002Fmin (Cockcroft-Gault formula calculated)；\n\n  (3). Echocardiogram\n* LVEF≥50%；\n\n  (4). electrocardiogram\n* The QT interval (QTcF) corrected by Fridericia method less than 450 ms for male and less than 470 ms for female.\n\n  9\\. Volunteer to join this study, sign informed consent, have good compliance and be willing to cooperate with follow-up.\n\nExclusion Criteria:\n\n1. There is a third interstitial fluid accumulation that cannot be controlled by drainage or other methods (such as a large amount of hydrothorax and ascites).\n2. Symptomatic or uncontrolled brain or meningeal metastases.\n3. Patients with only bone or skin metastasis as the assessable lesion.\n4. Previously suffered from other malignant tumors.\n5. Those who have used Eribulin during the advanced disease stage.\n6. Individuals with a known history of allergies to the components of the interventions; History of immunodeficiency, including HIV positive, other acquired or congenital immunodeficiency diseases and a history of organ transplantation.\n7. Any heart disease or other conditions evaluated unsuitable by the researcher.\n8. Pregnant and lactating female patients, female patients with fertility and positive baseline pregnancy test results, or female patients of reproductive age who are unwilling to take effective contraceptive measures throughout the trial period.\n9. According to the investigator's judgment, there are concomitant diseases that seriously endanger the patient's safety or affect the patient's completion of the study (including severe bleeding tendency, history of surgery within 2 weeks, hypertension beyond drug control, serious diabetes, active infection, thyroid disease, etc.).\n10. Having a clear history of neurological or mental disorders, including epilepsy or dementia.\n11. According to the RECIST 1.1 criteria, researchers determined that patients who received the last anti-tumor regimen before enrollment did not experience disease progression.","75 Years",{"count":143,"type":19},60,[50],"This study is a prospective, multicenter, phase II randomized clinical trial. It is planned to enroll 60 patients with advanced HER2 negative breast cancer, who will be randomly assigned to the experimental group and the control group in a 1:1 ratio. The participants will receive either eribulin combined with bevacizumab or eribulin monotherapy. Every treatment cycle will last for 21 days, with weekly monitoring of blood routine, blood biochemistry and other indicators. Imaging examinations will be conducted every two cycles and the efficacy will be evaluated according to RECIST 1.1 standard. The life quality questionnaire is arranged at baseline and every 3 months after enrollment, and the long-time survival will be followed every 3 months after treatment. The primary endpoint is progression-free survival (PFS), the secondary endpoints are objective response rate (ORR), clinical benefit rate (CBR) and overall survival (OS). The investigators will also focus on the treatment-related adverse events (TRAE) and quality of life (QoL) assessment.\n\nAt the same time, this study also aims to explore the resistant mechanisms of anti-angiogenic drugs. The investigators plan to collect peripheral venous blood samples at 3 time points: baseline, during treatment, and end of treatment. All the dynamic samples will be used for transcriptome sequencing to obtain the gene sets. And based on the optimal therapeutic efficacy, all the participants will be divided into response group and non-response group. GO and KEGG enrichment analysis will be subsequently performed between different therapeutic efficacy groups to draw gene interaction networks, identify key action nodes and explain the mechanism of anti-angiogenic drug resistance.",[147,148,24,149],"Breast Neoplasms","Neoplasm Metastasis","Bevacizumab",[151,152,153,154,155,156],"breast cancer","HER2 negative","eribulin","bevacizumab","efficacy","resistant mechanism","2024-08-01",{"date":159,"type":30},"2024-08-06",{"date":157,"type":19},{"date":162,"type":19},"2026-08-01",{"name":164,"class":37},"Wang Jiayu",3,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":141,"enrollmentInfo":173,"targetDuration":4,"studyType":48,"phases":175,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":38},"100553409","phase-2-efficacy-and-safety-of-trifluridinetipiracil-combined-with-fufuquitinib-for-third-line-treatment-of-mcrc-100553409","NCT06485713","Efficacy and Safety of Trifluridine\u002FTipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC","Efficacy and Safety of Trifluridine\u002FTipiracil Combined With Fufuquitinib Versus Trifluridine\u002FTipiracil and Fufuquitinib for Third-line Treatment of Unresectable Metastatic Colorectal Cancer","Inclusion Criteria:\n\n* 1.Age 18-75 (at the time of signing the informed consent);ECOG PS score: 0-1; Expected survival time \\> 3 months.\n\n  2.Patients with advanced colorectal adenocarcinoma confirmed by histopathology who had failed standard first - and second-line treatment.\n\n  3.At least 1 measurable lesion was present according to RECIST1.1 criteria. 4.Good organ function, laboratory tests meet the following criteria:\n  1. Hemoglobin ≥90g\u002FL;Absolute count of neutrophils (ANC) ≥1.5×109\u002FL;Platelet ≥100×109\u002FL;\n  2. ALT and AST≤2.5 upper limit of normal (ULN).ALP≤2.5 ULN;(if liver metastases ≤5 ULN);\n  3. Total bilirubin (TBIL) \\\u003C 1.5 ULN;\n  4. Serum creatinine (CR) \\\u003C1.5 ULN or creatinine clearance (CCR) ≥50ml\u002Fmin;\n  5. Serum albumin ≥30g\u002FL;\n  6. International Normalized ratio (INR), prothrombin time (PT), activated partial thrombin time (APTT) ≤1.5ULN;\n  7. Thyrotropin (TSH) ≤ULN;If abnormal, T3 and T4 levels should be investigated, and normal levels can be included.\n\n     5.cardiac color ultrasound: Left ventricular ejection fraction (LVEF) ≥50%. 6.Hypertension was well controlled. 7.Female participants of reproductive age should agree to use contraception during the study period and for 6 months after the study ends; Serum pregnancy test was negative within 7 days prior to study enrollment,and should be Non-lactation stage. Male subjects should agree to use contraception during the study period and for 6 months after the study ends.\n\n     Exclusion Criteria:\n* 1.Combined disease or history\n\n  1. .Present or present with other malignancies within 3 years.\n  2. .Have multiple factors affecting oral medication (such as inability to swallow, chronic diarrhea, or intestinal obstruction)\n  3. .Gastrointestinal bleeding or perforation occurred during the first 4 weeks of enrollment\n  4. .Patients with ulcerative colitis, Crohn's disease, and active inflammatory bowel disease during the first 4 weeks of enrollment\n  5. .Uncontrolled pleural effusion, ascites, and moderate or greater pericardial effusion\n  6. .Unmitigated toxic reactions above grade 1 of CTC AE due to any previous treatment, excluding alopecia.\n  7. .Received major surgical treatment or significant traumatic injury within 28 days prior to enrollment\n  8. .Patients with hematemesis, hematochezia, or any bleeding event ≥ CTCS AE level 3 within the previous 3 months, or with any signs of bleeding or history determined by the investigator to be ineligible for enrollment\n  9. .Arteriovenous thrombosis occurred within 6 months, such as cerebrovascular accident, pulmonary embolism, etc\n  10. .A history of psychotropic substance abuse and inability to abstain\n  11. .Subjects with any severe and\u002For uncontrolled disease, including\n\n      1. Uncontrolled hypertension\n      2. Unstable angina pectoris \u002F ≥ grade 2 cardiogenic chest pain;Myocardial infarction occurred within 12 months before randomization;≥ grade 2 heart failure;Restrictive heart disease;≥ grade 2 atrioventricular block, arrhythmia that cannot be stably controlled with drugs.\n      3. Active infection\n      4. Decompensated cirrhosis, active hepatitis;\n      5. Renal failure requires hemodialysis or peritoneal dialysis\n      6. A history of immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation\n\n      h.Diabetes with poorly controlled i.Urine routine showed urine protein ≥++, and 24h albuminuria quantitative \\> 1.0 g g.History of neurological or psychiatric disorders 2.Subjects who, in the investigator's judgment, have a concomitant medical condition that seriously endangers subjects' safety or interferes with the completion of the study, or are deemed unsuitable for enrollment for other reasons.",{"count":174,"type":19},200,[50],"To evaluate the efficacy and safety of trifluridine\u002Ftipiracil combined with fufuquitinib versus trifluridine\u002Ftipiracil and fufuquitinib in patients with unresectable metastatic colorectal cancer.",[178,24],"Metastatic Colorectal Cancer",[178,180,181,182],"Fufuquitinib","trifluridine\u002Ftipiracil","Combination therapy","2024-07-02",{"date":185,"type":30},"2024-07-03",{"date":187,"type":30},"2024-03-01",{"date":189,"type":19},"2026-06-01",{"name":191,"class":37},"First Affiliated Hospital of Wenzhou Medical University",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":201,"conditions":202,"keywords":206,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":38},"100439010","long-term-survivorship-of-discharged-patients-with-malignant-tumor-based-on-single-institutional-cancer-registry-100439010","NCT04996732","Long-term Survivorship of Discharged Patients With Malignant Tumor Based on Single-institutional Cancer Registry","Studies on Long-term Survivorship of Discharged Patients With Malignant Tumor Based on Fudan University Shanghai Cancer Center Registry（FUCaRe）","Inclusion Criteria:\n\n* All patients who completed tumor treatment (including surgery, radiotherapy, chemotherapy, immunotherapy, etc.) due to malignant tumors based on preoperative or intraoperative evaluation in Fudan University Shanghai Cancer Center during the study period.\n\nExclusion Criteria:\n\n* Patients who have not been treated during hospitalization;\n* Patients with non-malignant tumors.",{"count":200,"type":19},500000,"Real-world studies on long-term prognosis in patients who underwent anti-tumor treatments during hospitalization from a hospital-based cancer registry in china.",[23,203,204,205,24],"Survival","Surgery","Radiotherapy",[207,208],"Cancer","Survivorship","2021-08-02",{"date":211,"type":30},"2021-08-09",{"date":213,"type":30},"2008-01-01",{"date":215,"type":19},"2041-12-31",{"name":217,"class":37},"Fudan University",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":224,"targetDuration":226,"studyType":20,"phases":4,"briefSummary":222,"conditions":227,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":38},"100376673","registry-study-on-drug-therapy-and-clinical-outcomes-in-patients-with-acute-coronary-syndrome-100376673","NCT04184583","Registry Study on Drug Therapy and Clinical Outcomes in Patients With Acute Coronary Syndrome","Inclusion Criteria:\n\n* Informed consent has been signed.\n* Patients diagnosed in our hospital with acute coronary syndrome.\n* Age ≥18.\n* Life expectancy ≥12 months.\n\nExclusion Criteria:\n\n* Severe lack of important information such as history of previous medication, history of previous disease, history of surgery.\n* Pregnant and lactating women.\n* Mental disorders, or inability to communicate effectively with researchers, or failure to comply with research protocols.",{"count":225,"type":19},10000,"6 Years",[24,228],"Acute Coronary Syndrome","2019-11-29",{"date":231,"type":30},"2019-12-03",{"date":233,"type":19},"2019-12",{"date":235,"type":19},"2026-12",{"name":237,"class":37},"Beijing Anzhen Hospital"]